🇺🇸 FDA

Company profile · Sponsor

Bristol-Myers

Bristol-Myers Squibb / Pfizer EEIG

EB91877 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Bristol-Myers (EB91877) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EB91877
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. 5% Dextrose injection; Solution for injection/infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., 0.9% Sodium Chloride injection; Solution for injection/infusion

    Bristol-Myers

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  3. BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB

    Bristol-Myers

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  5. CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE

    Bristol-Myers

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  6. CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1

    Bristol-Myers

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  8. CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

    Bristol-Myers

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  9. Deucravacitinib placebo 3 mg film-coated tablets oral use, Deucravacitinib placebo 6 mg film-coated tablets oral use, deucravacitinib, deucravacitinib

    Bristol-Myers

    Sjogren's syndrome

    phase 3 small molecule active

    1 trial

  10. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  11. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  12. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  13. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  14. Humira 40 mg solution for injection in pre-filled syringe, Abatacept

    Bristol-Myers

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  15. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, Ipilimumab, Sutent 12.5 mg hard capsules, Sutent 12.5 mg hard capsules

    Bristol-Myers

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  17. KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC, KarXT, KarXT

    Bristol-Myers

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  18. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  19. KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT

    Bristol-Myers

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  20. KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  21. KarXT, KarXT Matching Placebo, KarXT, KarXT

    Bristol-Myers

    Schizophrenia

    phase 3 small molecule active

    1 trial

  22. KarXT, KarXT, KarXT, KarXT

    Bristol-Myers

    Mania or Mania with Mixed Features in Bipolar-I Disorder

    phase 3 small molecule active

    1 trial

  23. KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  24. KarXT, KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Bristol-Myers?

Bristol-Myers (EB91877) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Bristol-Myers sponsor?

We track 24 ClinicalTrials.gov-linked programs for Bristol-Myers, including "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Bristol-Myers company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.